Profitability came under strain. Gross profit fell to EUR 246m, with margins narrowing to 23.7% as negative product mix—particularly in Asia Pacific—weighed on performance
The Pharmaceuticals portfolio and pipeline are more promising than perhaps ever before
Our company is prioritising deeper collaborations with CDMOs and biosimilar companies as part of its strategy to expand its footprint across India, Middle East, and Africa region
The study evaluated oral semaglutide in young patients with type 2 diabetes and found it delivered a superior reduction in HbA1c
Aims to boost speed & precision in patient care
Collaboration integrates SmartChip PCR technology with cloud-based analytics to enable faster, standardised monitoring of antimicrobial resistance
New facility offers genetic testing, counselling and personalised treatment plans to enable early diagnosis and precision-led care
Denosumab biosimilars approved in Canada to expand access for osteoporosis and cancer-related bone conditions
The transition from an outsourced MRI model to an in-house facility marks more than an infrastructure upgrade
Deal includes 13 branded generic products across 55+ countries; acquisition expected to strengthen global anti-infective portfolio and expand regulated market presence
Subscribe To Our Newsletter & Stay Updated
